Effect of Dillenia capsule on quality of sleep, anxiety, stress, and depression.

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

TCTR

Registry ID

TCTR20230127006

Enrollment

Registered

2023-01-27

Start date

2025-03-03

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy condition Dillenia Quality of sleep Anxiety Stress Depression

Interventions

Subjects will receive the placebo product which has the same color and smell and looks like a Dillenia capsule.,Subjects will receive capsules containing Dillenia powder at dose 1 g per day.,Subjects

Placebo Comparator Other,Experimental Other,Experimental Other

Placebo,Dillenia capsule 1 g/day,Dillenia capsule 2 g/day

Eligibility

Sex/Gender

All

Age

30 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged between 30-65 years old who live in Northeastern of Thailand 2. Don't have menopause syndromes.

Exclusion criteria

Exclusion criteria: 1. Volunteers who have been diagnosed with one of the following; heart disease, lung disease or allergies, diabetes, high blood pressure, hyperlipidemia, liver disease, kidney disease, cancer, autoimmune disease, hematological disorder, gout or high uric acid, head injury and mental disorder 2. Volunteers who were exposed to pesticides before the test 3. Hysterectomy and/or Oophorectomy 4. Volunteers who use hormones or any drug that effect on Hypothalamic Pituitary Gonadal axis 5. Volunteers who require supplements or any drug that affect the nervous system and bone before the start of the test 6. Volunteers who require supplements or any drug that affect the nervous system by order of the doctor before the start of the test 7. Drinking alcohol more than 5 times per day 8. Smoking more than 10 pieces per day 9. Volunteers who participate in other projects 10. During breastfeeding

Design outcomes

Primary

Measure	Time frame
Quality of sleep, Stress, anxiety, depression 2 months questionnaires; Depression Anxiety Stress Scale 21 Thai, Pittsburgh Sleep Quality Index (PSQI)	—

Secondary

Measure	Time frame
Evaluation of Monoamine oxidase (MAO), Monoamine oxidase type A and type B, GABA transaminase (GABA-T) and Cortisol 2 months laboratory,Evaluation of Inflammatory markers; Interleukin-6 (IL-6) and C-reactive protein (CRP) 2 months laboratory,Mood evaluation using MOSAIC 2 months questionnaires,Beck Anxiety Inventory (BAI) 2 months questionnaires,Penn State Worrying Questionnaire (PSWQ) 2 months questionnaires	—

Measure

Time frame

Evaluation of Monoamine oxidase (MAO), Monoamine oxidase type A and type B, GABA transaminase (GABA-T) and Cortisol 2 months laboratory,Evaluation of Inflammatory markers; Interleukin-6 (IL-6) and C-reactive protein (CRP) 2 months laboratory,Mood evaluation using MOSAIC 2 months questionnaires,Beck Anxiety Inventory (BAI) 2 months questionnaires,Penn State Worrying Questionnaire (PSWQ) 2 months questionnaires

—

Countries

Thailand

Contacts

Public ContactPongsatorn Paholpak

Faculty of Medicine, Khon Kaen University

ppaholpak@kku.ac.th66894221147

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026